

ACI Formulations PLC

1st Quarter Report 2025-2026

ACI Formulations PLC


Statement of financial position
Unaudited

Figures in "000"

<i>In Taka</i>	Note	As at 30 Sep 2025	As at 30 Jun 2025
Assets			
Property, plant and equipment	5	2,677,976	2,662,168
Right-of-use assets		20,605	23,291
Investments	6	83,552	83,552
Non-current assets		2,782,132	2,769,011
Inventories	8	1,665,624	1,469,898
Trade receivables	9	1,492,926	1,318,352
Other receivables		74,945	64,258
Inter-company receivables	10	2,378,854	2,050,805
Advances, deposits and prepayments	11	196,270	202,043
Current tax assets		485,803	486,847
Cash and cash equivalents		48,653	242,556
Current assets		6,343,076	5,834,760
Total assets		9,125,208	8,603,771
Equity			
Share capital		472,500	472,500
Revaluation reserve		1,475,889	1,475,889
Retained earnings		1,704,560	1,618,503
Total equity		3,652,950	3,566,892
Liabilities			
Employee benefits	12	70,308	67,965
Lease liabilities		26,929	29,331
Deferred tax liabilities		192,081	199,583
Non-current liabilities		289,318	296,879
Bank overdrafts		180,396	245,034
Loans and borrowings		4,184,031	3,643,054
Lease liabilities- current portion		15,260	13,157
Trade payables		122,508	163,427
Other payables	13	656,725	651,258
Unclaimed dividend account	14	1,660	1,699
Inter-company payables	15	22,359	22,372
Current liabilities		5,182,940	4,740,000
Total liabilities		5,472,258	5,036,879
Total equity and liabilities		9,125,208	8,603,771
Net asset value (NAV) per share		77.31	75.49




Managing Director

Director

Chief Financial Officer



Company Secretary

ACI Formulations PLC

Statement of profit or loss and other comprehensive income
Unaudited

<i>In Taka</i>	Note	Figures in "000"	
		For the 1st quarter ended from	
		July 2025 to September 2025	July 2024 to September 2024
Revenue	16	1,333,339	1,212,300
Cost of sales	17	(907,467)	(786,060)
Gross profit		425,871	426,240
Other income		4,802	5,221
Administrative, selling and distribution expenses	18	(237,862)	(198,213)
Operating profit		192,811	233,248
Finance costs, net		(56,692)	(72,036)
Profit before contribution to WPPF		136,119	161,213
Contribution to WPPF		(6,806)	(8,061)
Profit before tax		129,313	153,152
Tax expenses		(43,256)	(42,528)
Profit after tax		86,057	110,624
Other comprehensive income		-	-
Total comprehensive income		86,057	110,624
Earnings per share			
Basic earnings per share (BEPS)		1.82	2.34



Managing Director



Director



Chief Financial Officer



Company Secretary

ACI Formulations PLC

Statement of changes in equity
Unaudited

Figures in "000"

<i>In Taka</i>	For the 1st quarter ended 30 September 2025			
	Attributable to owner of the Company			Total
	Share capital	Revaluation reserve	Retained earnings	
Balance at 1 July 2025	472,500	1,475,889	1,618,503	3,566,892
Total comprehensive income				
Profit for the period	-	-	86,057	86,057
Total comprehensive income	-	-	86,057	86,057
Transactions with owners of the company				
Contributions and distributions				
Dividends	-	-	-	-
Total transactions with owners of the company	-	-	-	-
Balance at 30 September 2025	472,500	1,475,889	1,704,560	3,652,950

<i>In Taka</i>	For the 1st quarter ended 30 September 2024			
	Attributable to owner of the Company			Total
	Share capital	Revaluation reserve	Retained earnings	
Balance at 1 July 2024	472,500	1,442,196	1,345,681	3,260,377
Total comprehensive income				
Profit for the period	-	-	110,624	110,624
Total comprehensive income	-	-	110,624	110,624
Transactions with owners of the company				
Contributions and distributions				
Dividends	-	-	-	-
Total transactions with owners of the company	-	-	-	-
Balance at 30 September 2024	472,500	1,442,196	1,456,305	3,371,001

ACI Formulations PLC

Statement of cash flows
Unaudited

Figures in "000"

<i>In Taka</i>	Note	For the 1st quarter ended from	
		July 2025 to September 2025	July 2024 to September 2024
Cash flows from operating activities			
Cash received from customers and others		1,157,366	1,072,826
Cash paid to suppliers and employees		(1,387,886)	(1,160,187)
Cash (used in)/generated from operating activities		(230,520)	(87,360)
Interest paid		(28,030)	(48,066)
Income tax paid		(49,713)	(48,475)
		(77,743)	(96,541)
Net cash (used in)/generated from operating activities*	19	(308,263)	(183,901)
Cash flows from investing activities			
Acquisition of property, plant and equipment		(28,787)	(15,941)
Sales proceed from disposal		-	4,534
Net cash (used in)/generated from investing activities		(28,787)	(11,407)
Cash flows from financing activities			
Inter-company debts received/(paid)		(328,062)	(28,529)
Proceeds from loans and borrowings		540,978	224,660
Payment for lease liability		(5,091)	(3,263)
Dividends paid		(39)	(3)
Net cash (used in)/generated from financing activities		207,786	192,865
Net (decrease)/increase in cash and cash equivalents		(129,265)	(2,444)
Cash and cash equivalents as at 1 July		(2,478)	(390)
Effect of foreign exchange rate changes		-	-
Cash and cash equivalents as at 30 September		(131,743)	(2,834)
Closing balance represents			
Cash and cash equivalents		48,653	288,549
Bank overdraft		(180,396)	(291,383)
		(131,743)	(2,834)
Net operating cash flow per share (NOCFPS)		(6.52)	(3.89)

* See Note 19 for reconciliation of net operating cash flow.

ACI Formulations PLC
Consolidated Statement of Financial Position
Unaudited

Figures in "000"

<i>In Taka</i>	Note	As at 30 Sep 2025	As at 30 Jun 2025
Assets			
Property, plant and equipment	5(a)	2,677,976	2,662,177
Right-of-use assets		20,605	23,291
Investments	6(a)	61,604	61,604
Intangible assets	7	5,148	5,148
Non-current assets		2,765,332	2,752,220
Inventories	8(a)	1,665,624	1,469,898
Trade receivables	9(a)	1,494,806	1,320,125
Other receivables		74,895	63,685
Inter-company receivable	10(a)	2,376,352	2,046,816
Advances, deposits and prepayments	11(a)	196,725	202,407
Current tax assets		483,706	485,296
Cash and cash equivalents		50,586	244,488
Current assets		6,342,694	5,832,716
Total assets		9,108,026	8,584,935
Equity			
Share capital		472,500	472,500
Revaluation reserve		1,475,889	1,475,889
Retained earnings		1,706,852	1,619,234
Equity attributable to the owner of the Company		3,655,241	3,567,623
Non controlling interest		2,261	2,182
Total equity		3,657,503	3,569,806
Liabilities			
Employee benefits	12	70,308	67,965
Lease liabilities		26,929	29,331
Deferred tax liabilities		192,081	199,583
Non-current liabilities		289,318	296,879
Bank overdrafts		180,396	245,034
Loans and borrowings		4,184,031	3,643,054
Lease liabilities- current portion		15,260	13,157
Trade payables		122,824	163,743
Other payables	13(a)	657,032	651,564
Unclaimed dividend account	14	1,660	1,699
Current liabilities		5,161,205	4,718,251
Total liabilities		5,450,523	5,015,130
Total equity and liabilities		9,108,026	8,584,935
Net asset value (NAV) per share	20	77.36	75.51



Managing Director



Director



Chief Financial Officer



Company Secretary

ACI Formulations PLC

Consolidated statement of profit or loss and other comprehensive income
Unaudited

Figures in "000"

<i>In Taka</i>	Note	For the 1st quarter ended from	
		July 2025 to September 2025	July 2024 to September 2024
Revenue	16(a)	1,335,025	1,212,944
Cost of sales	17(a)	(907,467)	(786,060)
Gross profit		427,557	426,883
Other income		4,802	5,221
Administrative, selling and distribution expenses	18(a)	(237,872)	(198,283)
Operating profit		194,487	233,822
Finance costs, net		(56,182)	(71,626)
Profit before contribution to WPPF		138,305	162,196
Contribution to WPPF		(6,806)	(8,061)
Profit before tax		131,499	154,135
Income tax expenses		(43,802)	(42,845)
Profit after tax		87,697	111,290
Other comprehensive income		-	-
Total comprehensive income		87,697	111,290
Total comprehensive income attributable to:			
Owners of the Company		87,618	111,242
Non controlling interest		79	48
		87,697	111,290
Earnings per share			
Basic earnings per share (BEPS)	20	1.85	2.35



Managing Director



Director



Chief Financial Officer



Company Secretary

ACI Formulations PLC

Consolidated statement of changes in equity
Unaudited

Figures in "000"

For the 1st quarter ended 30 September 2025						
<i>In Taka</i>	Attributable to owner of the Company			Total	Non-controlling interests	Total equity
	Share capital	Revaluation reserve	Retained earnings			
Balance at 1 July 2025	472,500	1,475,889	1,619,234	3,567,623	2,182	3,569,806
Total comprehensive income						
Profit for the period	-	-	87,618	87,618	79	87,697
Total comprehensive income	-	-	87,618	87,618	79	87,697
Transactions with owners of the company						
Contributions and distributions						
Dividends	-	-	-	-	-	-
Total transactions with owners of the company	-	-	-	-	-	-
Balance at 30 September 2025	472,500	1,475,889	1,706,852	3,655,241	2,261	3,657,503
For the 1st quarter ended 30 September 2024						
<i>In Taka</i>	Attributable to owner of the Company			Total	Non-controlling interests	Total equity
	Share capital	Revaluation reserve	Retained earnings			
Balance at 1 July 2024	472,500	1,442,196	1,342,956	3,257,652	1,985	3,259,637
Total comprehensive income						
Profit for the period	-	-	111,242	111,242	48	111,290
Total comprehensive income	-	-	111,242	111,242	48	111,290
Transactions with owners of the company						
Contributions and distributions						
Dividends	-	-	-	-	-	-
Total transactions with owners of the company	-	-	-	-	-	-
Balance at 30 September 2024	472,500	1,442,196	1,454,198	3,368,894	2,034	3,370,928

ACI Formulations PLC
Consolidated statement of cash flows
Unaudited

Figures in "000"

<i>In Taka</i>	Note	For the 1st quarter ended from	
		July 2025 to September 2025	July 2024 to September 2024
Cash flows from operating activities			
Cash received from customers and others		1,158,944	1,073,752
Cash paid to suppliers and employees		(1,387,977)	(1,160,145)
Cash (used in)/generated from operating activities		(229,033)	(86,393)
Interest paid		(27,520)	(47,657)
Income tax paid		(49,713)	(48,475)
		(77,233)	(96,132)
Net cash (used in)/generated from operating activities*	19 (a)	(306,266)	(182,525)
Cash flows from investing activities			
Acquisition of property, plant and equipment		(28,787)	(15,941)
Sales proceed from disposal		-	4,534
Net cash (used in)/generated from investing activities		(28,787)	(11,407)
Cash flows from financing activities			
Inter-company debts received/(paid)		(330,059)	(29,930)
Proceeds from loans and borrowings		540,978	224,660
Payment for lease liability		(5,091)	(3,263)
Dividends paid		(39)	(3)
Net cash (used in)/generated from financing activities		205,789	191,464
Net (decrease)/increase in cash and cash equivalents		(129,265)	(2,468)
Cash and cash equivalents as at 1 July		(546)	2,638
Cash and cash equivalents as at 30 September		(129,810)	170
Closing balance represents			
Cash and cash equivalents		50,586	291,553
Bank overdraft		(180,396)	(291,383)
		(129,810)	170
Net operating cash flow per share (NOCFPS)	20	(6.48)	(3.86)

* See Note 19(a) for reconciliation of consolidated net operating cash flow.

ACI Formulations PLC

Notes to the financial statements as at and for the 1st quarter ended on 30 September 2025 Unaudited

1 Company profile:

ACI Formulations PLC, a subsidiary of Advanced Chemical Industries PLC, domiciled in Bangladesh. The company's shares are listed with both Dhaka Stock Exchange Limited and Chittagong Stock Exchange Limited. The Principal activities of the company are manufacturing and marketing of a number of agrochemical, consumer brand and paint products.

2 Subsidiaries of ACI Formulations PLC:

Neem Laboratories (Pvt.) Ltd.

The Company acquired 98% shares of Neem Laboratories (Pvt.) Ltd. The initial effective date of acquisition was 28 February 2014. Neem Laboratories (Pvt.) Ltd generate its revenue through royalty fees based on the renewed agreement with ACI PLC effective from 1 July 2024 for a tenure of 5 years; and being engaged in the manufacturing of products under the Neem brand name. Since the Subsidiary showed profitability during the year, its ability to operate as a going concern is not at risk.

ACI AgroChem (Pvt.) Ltd.

ACI AgroChem was incorporated on 22nd June 2022 as a limited Company. The principal activities of the Company is to manufacture and marketing of various kinds of agricultural input like chemical including other allied and general chemical. The Company is yet to start its operation. ACI Formulations PLC holds 90% shares of ACI AgroChem Limited.

3 Consolidated Financial statements:

In addition to the separate financial statements, the consolidated financial statements of the company have been prepared and included in this interim financial report as per IFRS 10: Consolidated Financial Statements. In separate Financial Statements, investment in subsidiaries has been carried at cost as per IAS 27: Separate Financial Statements.

4 Selected explanatory notes:

These financial statements have been prepared in line with Accounting Policies as adopted in the preparation of financial statements for the year ended 30 June 2025. This interim financial report includes only those selected explanatory notes as were deemed appropriate for better understanding of unaudited financial statements.

		Figures in '000'	
		30 Sep 2025	30 Jun 2025
		Taka	Taka
5	Property, plant & equipment		
	Opening balance	3,141,178	2,979,040
	Addition during the period/year	28,740	173,443
	Adjustment/disposal during the period/year	(3,700)	(11,306)
		<u>3,166,218</u>	<u>3,141,178</u>
	Accumulated depreciation at the end of period/year	(488,242)	(479,009)
	Closing balance	<u><u>2,677,976</u></u>	<u><u>2,662,168</u></u>

	<u>30 Sep 2025</u>	<u>30 Jun 2025</u>
	<u>Taka</u>	<u>Taka</u>
5(a) Consolidated property, plant & equipment		
Opening balance	3,141,186	2,979,049
Addition during the period/year	28,740	173,443
Adjustment/disposal during the period/year	(3,709)	(11,306)
	<u>3,166,218</u>	<u>3,141,186</u>
Accumulated depreciation at the end of period/year	(488,242)	(479,009)
Closing balance	<u><u>2,677,976</u></u>	<u><u>2,662,177</u></u>
6 Investments		
Investment in subsidiaries	21,948	21,948
Investment in FDR	61,529	61,529
Investment in shares of ACI Motors Limited	75	75
	<u><u>83,552</u></u>	<u><u>83,552</u></u>
6(a) Consolidated investments		
Investment in FDR	61,529	61,529
Investment in Shares- ACI Motors Limited	75	75
	<u><u>61,604</u></u>	<u><u>61,604</u></u>
7 Intangible assets		
Goodwill on acquisition :		
Neem Laboratories (Pvt.) Limited	5,148	5,148
	<u><u>5,148</u></u>	<u><u>5,148</u></u>
8 Inventories		
Raw and packing materials	892,134	546,150
Finished goods	735,022	618,605
Goods in transit	45,170	310,761
Other inventories	26,035	26,586
Allowances for slow moving inventory	(32,736)	(32,204)
	<u><u>1,665,624</u></u>	<u><u>1,469,898</u></u>
8(a) Consolidated inventories		
Raw and packing materials	892,134	546,150
Finished goods	735,298	618,882
Goods in transit	45,170	310,761
Other inventories	26,035	26,586
Allowances for slow moving inventory	(33,012)	(32,480)
	<u><u>1,665,624</u></u>	<u><u>1,469,898</u></u>
9 Trade receivables		
Related parties	6,384	7,094
Other than related parties	1,743,609	1,566,156
	<u><u>1,749,993</u></u>	<u><u>1,573,249</u></u>
Allowances for doubtful debts	(257,067)	(254,897)
	<u><u>1,492,926</u></u>	<u><u>1,318,352</u></u>
Below six months	1,249,564	1,057,170
Over six months	500,429	516,080
Allowances for doubtful debts	(257,067)	(254,897)
	<u><u>1,492,926</u></u>	<u><u>1,318,352</u></u>
9(a) Consolidated trade receivables		
Related parties	6,384	7,094
Other than related parties	1,745,489	1,567,929
	<u><u>1,751,874</u></u>	<u><u>1,575,022</u></u>
Allowances for doubtful debts	(257,067)	(254,897)
	<u><u>1,494,806</u></u>	<u><u>1,320,125</u></u>
Below six months	1,249,991	1,057,597
Over six months	501,883	517,425
Allowances for doubtful debts	(257,067)	(254,897)
	<u><u>1,494,806</u></u>	<u><u>1,320,125</u></u>

	<u>30 Sep 2025</u>	<u>30 Jun 2025</u>
	<u>Taka</u>	<u>Taka</u>
10 Inter-company receivables		
ACI PLC	2,317,280	1,990,274
ACI HealthCare Bangladesh Ltd.	54,376	53,333
Neem Laboratories (Pvt.) Ltd.	7,198	7,198
	<u>2,378,854</u>	<u>2,050,805</u>
10(a) Consolidated inter-company receivables		
ACI PLC	2,321,975	1,993,483
ACI HealthCare USA Inc.	54,376	53,333
	<u>2,376,352</u>	<u>2,046,816</u>
11 Advances, deposits & prepayments		
Advances:		
Staffs	239	9
Suppliers & others	12,057	15,424
VAT current account	36,278	24,965
	<u>48,574</u>	<u>40,399</u>
Deposits:		
Security deposits	10,146	10,146
LC Margin	130,534	147,557
Bank guarantee margin	2,339	2,339
	<u>143,019</u>	<u>160,042</u>
Prepayments:		
Prepaid expenses	4,677	1,602
	<u>4,677</u>	<u>1,602</u>
	<u>196,270</u>	<u>202,043</u>
11(a) Consolidated advances, deposits & prepayments		
Advances:		
Staff	239	9
Suppliers & others	12,512	15,789
VAT current account	36,278	24,965
	<u>49,029</u>	<u>40,763</u>
Deposits:		
Security deposits	10,146	10,146
LC Margin	130,534	147,557
Bank guarantee margin	2,339	2,339
	<u>143,019</u>	<u>160,042</u>
Prepayments:		
Prepaid expenses	4,677	1,602
	<u>4,677</u>	<u>1,602</u>
	<u>196,725</u>	<u>202,407</u>
12 Employee benefits		
Defined benefit obligation	50,531	48,337
Other employee benefits	19,778	19,628
	<u>70,308</u>	<u>67,965</u>
13 Other payables		
Creditor for expenses	353,893	384,702
Advance from customer	6,515	18,753
Interest payable	124,157	95,495
Security money payable	126,125	107,207
Withholding tax and VAT payable	13,665	19,537
Workers' profit participation fund	32,370	25,564
	<u>656,725</u>	<u>651,258</u>

	<u>30 Sep 2025</u>	<u>30 Jun 2025</u>
	<u>Taka</u>	<u>Taka</u>
13(a) Consolidated other payables		
Creditor for expenses	354,200	385,008
Advance from customer	6,515	18,753
Interest payable	124,157	95,495
Security money payable	126,125	107,207
Withholding tax and VAT payable	13,665	19,537
Provision for workers' profit participation fund	32,370	25,564
	<u>657,032</u>	<u>651,564</u>
14 Unclaimed dividend account		
Unclaimed/ unpaid dividend	1,660	1,699
	<u>1,660</u>	<u>1,699</u>
15 Inter-company payables		
ACI AgroChem Limited	22,359	22,372
	<u>22,359</u>	<u>22,372</u>
	<u>for the period from</u>	
	<u>July 2025 to</u>	<u>July 2024 to</u>
	<u>September</u>	<u>September</u>
	<u>2025</u>	<u>2024</u>
	<u>Taka</u>	<u>Taka</u>
16 Revenue		
Crop Care & Public Health	1,012,990	987,484
Mosquito Coil	-	478
Aerosol	193,098	143,343
Paint	123,772	77,789
Others	3,479	3,205
	<u>1,333,339</u>	<u>1,212,300</u>
16(a) Consolidated revenue		
Crop Care & Public Health	1,012,990	987,484
Mosquito Coil	-	478
Aerosol	193,098	143,343
Paint	123,772	77,789
Others	5,165	3,849
	<u>1,335,025</u>	<u>1,212,944</u>

		for the period from	
		July 2025 to September 2025	July 2024 to September 2024
		Taka	Taka
17	Cost of sales		
	Opening stock	1,164,755	1,143,347
	Purchase	1,308,799	968,690
	Stock write off	605	3,751
		2,474,159	2,115,788
	Closing stock	(1,627,155)	(1,383,468)
		847,004	732,320
	Manufacturing expenses	60,464	53,740
		907,467	786,060
17(a)	Consolidated cost of sales		
	Opening stock	1,164,755	1,143,347
	Purchase	1,308,799	968,690
	Stock write off	605	3,751
		2,474,159	2,115,788
	Closing stock	(1,627,155)	(1,383,468)
		847,004	732,320
	Manufacturing expenses	60,464	53,740
		907,467	786,060
18	Administrative, selling and distribution expenses		
	Administrative expenses	64,321	57,221
	Distribution expenses	37,185	26,901
	Selling expenses	136,356	114,091
		237,862	198,213
18(a)	Consolidated administrative, selling and distribution		
	Administrative expenses	64,331	57,291
	Distribution expenses	37,185	26,901
	Selling expenses	136,356	114,091
		237,872	198,283
19	Reconciliation of net operating cash flow		
		for the period from	
		July 2025 to September 2025	July 2024 to September 2024
<i>In Taka</i>			
	Profit after tax	86,057	110,624
	Adjustment for non cash items and others:		
	- Depreciation and amortization	12,980	11,302
	- Provisions	2,508	5,014
	- Net finance cost	28,662	23,969
	- Tax expense	(6,458)	(5,947)
	- Contribution to WPPF	6,806	8,061
	- Gain/ loss on asset disposal	-	(3,439)
	Changes in:		
	- Inventories	(195,653)	(136,751)
	- Trade and other receivables	(187,769)	(146,271)
	- Advances, deposit and prepayments	5,773	6,596
	- Trade and other payables, employment benefits' and others	(61,170)	(57,060)
	Cash generating from operating activities	(308,263)	(183,901)

19 (a)

Reconciliation of consolidated net operating cash flow

<i>In Taka</i>	for the period from	
	July 2025 to September 2025	July 2024 to September 2024
Profit after tax	87,697	111,290
Adjustment for:		
- Depreciation and amortization	12,998	11,320
- Bad debts and inventory loss/(recovery)	2,508	5,014
- Net finance cost	28,662	23,969
- Tax expense	(6,141)	(5,630)
- Contribution to WPPF	6,806	8,061
- Gain/ loss on asset disposal	-	(3,439)
Changes in:		
- Inventories	(195,653)	(136,751)
- Trade and other receivables	(187,487)	(145,989)
- Advances, deposit and prepayments	5,839	6,662
- Trade and other payables, employment benefits' and others	(61,496)	(57,034)
Cash generating from operating activities	(306,266)	(182,525)

for the period upto	
July 2025 to September 2025	July 2024 to September 2024

20 Consolidated EPS, NAV per Share and NOCFPS:

Weighted average number of ordinary shares (in thousand)	47,250	47,250
Consolidated profit attributable to equity holders of the Company (Taka '000)	87,618	111,242
Earnings per share (Taka)	1.85	2.35
Consolidated cash flows from operating activities (Taka '000)	(306,266)	(182,525)
Net operating cash flows per share (NOCFPS)	(6.48)	(3.86)
	30 Sep 2025	30 Jun 2025
	Taka	Taka
Consolidated net asset attributable to equity holders of the	3,655,241	3,567,623
Net asset value (NAV) per share	77.36	75.51

Consolidated revenue increased by 10% over SPLY . Despite that GP increased by 0.16% due to increase of raw material and packing material price in the international market. On other hand, overall operating expenses increased by 20% due to inflationary effects and higher cost of exports. On the other hand, financing cost reduced by 22% due to fluctuation gain resulted from trade financing. Overall effect resulted consolidated profit after tax of Tk. 87.70 Mn against Tk 111.29 Mn of SPLY resulting in lower consolidated EPS. On the other hand, consolidated NOCFPS decreased due to ensure adequate inventory in the upcoming season over SPLY.

21 Segment reporting

The Company has four reportable segments, as described below, which are the Company's strategic divisions. The strategic divisions offer different products and services, and are managed separately because they require different technology and marketing strategies. For each of the strategic divisions, the Company's CEO reviews internal management reports at least on a quarterly basis. The following summary describes the operations in each of the Company's reportable segments:

Crop Care and Public Health (CC & PH) To manufacture and sell crop care and public health products.

Mosquito Coil (M Coil) To manufacture and sell mosquito coil products

Aerosol To manufacture and sell aerosol and air freshener products.

Paint To manufacture and sell of paint products.

Figures in '000'

Particulars	CC & PH		M Coil		Aerosol		Paint		Unallocated		Total	
	1st quarter ended on		1st quarter ended on		1st quarter ended on		1st quarter ended on		1st quarter ended on		1st quarter ended on	
	30-Sep-25	30-Sep-24	30-Sep-25	30-Sep-24	30-Sep-25	30-Sep-24	30-Sep-25	30-Sep-24	30-Sep-25	30-Sep-24	30-Sep-25	30-Sep-24
	Taka	Taka	Taka	Taka	Taka	Taka	Taka	Taka	Taka	Taka	Taka	Taka
Segment revenue:												
External revenues	1,012,990	987,484	-	478	193,098	142,981	123,772	77,789	3,479	3,205	1,333,339	1,211,938
Inter-segment revenues	-	-	-	-	-	362	-	-	1,686	644	1,686	1,006
Total revenue	1,012,990	987,484	-	478	193,098	143,343	123,772	77,789	5,165	3,849	1,335,025	1,212,944
Cost of sales excluding depreciation	(606,953)	(567,644)	(819)	(7,508)	(187,737)	(132,389)	(98,407)	(65,223)	(5,592)	(5,375)	(899,508)	(778,139)
Depreciation	(7,676)	(5,875)	(2,370)	(2,874)	(1,416)	(1,342)	(1,262)	(1,039)	(256)	(172)	(12,980)	(11,302)
Other income /(expense)	2,960	1,545	1,738	3,595	12	72	-	-	93	13	4,802	5,224
Operating expenses excluding depreciation	(188,669)	(155,569)	(256)	(1,910)	(3,177)	(2,447)	(40,271)	(34,945)	(446)	78	(232,819)	(194,793)
Financing costs	(37,870)	(53,209)	-	(72)	(7,913)	(8,684)	(10,206)	(8,922)	(193)	(742)	(56,182)	(71,629)
Profit before tax	166,183	196,396	(1,623)	(7,876)	(6,783)	(1,374)	(25,077)	(30,723)	(1,201)	(2,232)	131,499	154,135
Reportable segment assets	3,475,907	3,316,182	157,750	166,515	644,525	662,489	704,519	639,036	4,125,326	3,800,713	9,108,026	8,584,935
Reportable segment liabilities	1,771,899	1,669,320	19,281	14,373	266,700	272,227	169,720	172,704	3,222,923	2,886,506	5,450,523	5,015,130

* Comparative figures of segment assets and segment liabilities are as of 30 June 2025.

22 Figures have been rounded off to the nearest '000' Taka and previous period's figures have been rearranged to conform to current period's presentation.